Clinical Study of POSS-PCU Vascular Grafts for Vascular Access

Not Applicable

Not yet recruiting

• Conditions: Renal Insufficiency
• Interventions: Device: POSS-PCU vascular graft

• Registration Number: NCT02301312
• Lead Sponsor: University College, London

Brief Summary

This study evaluates the safety and performance of a new vascular graft made of POSS-PCU as a vascular access conduit for haemodialysis. 30 patients requiring access for dialysis will be enrolled and monitored at regular intervals for 18 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-11-21
• Study First Submitted QC: 2014-11-24
• Study First Posted: 2014-11-25
• Status Verified: 2019-10
• Last Update Submitted: 2020-04-17
• Last Update Posted: 2020-04-20
• Study Start: 2021-04
• Primary Completion: 2025-04
• Study Completion: 2025-04

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Subjects requiring vascular access for haemodialysis

• Subjects with no suitable vein.

• Subjects aged 18 - 80 years old

• Subjects are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained

• Patients of child bearing potential, who are sexually active, must agree to the use of 2 highly effective forms of contraception throughout their participation in the study and for 6 months after completion of treatment:

  • Condom with spermicide.

AND 1 of the following:

• Oral contraceptive or hormonal therapy (e.g. hormone implants).
• Placement of an intra-uterine device.

Exclusion Criteria

• Subjects with predicted short-term survival (less than 18 months) or poor prognosis (this will be on the discretion of the clinician in charge)
• Subjects with left ventricle ejection fraction (LVEF) <20% diagnosed on ECHO either pre-procedure or documented within the previous 3 months prior to consent.
• Pregnant or lactating
• Allergies to any constituents of the graft material
• Patients who are infected or colonized with Methicillin Resistant Staphylococcus Aureus (MRSA).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
POSS-PCU graft	POSS-PCU vascular graft	POSS-PCU vascular graft will be used to create vascular access for dialysis.

Primary Outcome Measures

Name	Time	Method
Patency rate	18 months	The primary performance end point of the study is the patency rate of the POSS-PCU graft at the end of the 18 months as measured with US Doppler, which will be compared to the known patency rate for the PTFE graft
Safety endpoint of this study is defined as any Serious Adverse Event related to the implantation procedure or device implantation within 30 days of implantation procedure	30 days

Secondary Outcome Measures

Name	Time	Method
Patency rate	12 months	Patency rate of POSS-PCU Graft at 2weeks, 3, 6, and 12 months as measured with US Doppler.
Secondary patency rate	18 months	Any surgical or endovascular intervention required to maintain the patency of the grafts up to the 18 month time point.